Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies.
PD-1
WT1
cancer vaccine
combination therapy
glioblastoma
immunotherapy
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Wilms' tumor gene 1 (WT1) peptide vaccine and anti-programmed cell death-1 (anti-PD-1) antibody are expected as immunotherapies to improve the clinical outcome of glioblastoma. The aims of this study were to clarify how each immunotherapy affects tumor-infiltrating immune cells (TIIs) and to determine whether the combination of these two therapies could synergistically work. Mice were transplanted with WT1 and programmed cell death-ligand 1 doubly expressing glioblastoma cells into brain followed by treatment with WT1 peptide vaccine, anti-PD-1 antibody, or the combination of the two, and survival of each therapy was compared. CD45 Most mice seemed to be cured by the combination therapy with WT1 peptide vaccine and anti-PD-1 antibody, which was much better survival than each monotherapy. A large number of CD4 Our results clearly demonstrated that WT1 peptide vaccine and anti-PD-1 antibody therapies worked in the different steps of cancer-immunity cycle and that the combination of the two therapies could work synergistically against glioblastoma.
Sections du résumé
BACKGROUND
BACKGROUND
Wilms' tumor gene 1 (WT1) peptide vaccine and anti-programmed cell death-1 (anti-PD-1) antibody are expected as immunotherapies to improve the clinical outcome of glioblastoma. The aims of this study were to clarify how each immunotherapy affects tumor-infiltrating immune cells (TIIs) and to determine whether the combination of these two therapies could synergistically work.
METHODS
METHODS
Mice were transplanted with WT1 and programmed cell death-ligand 1 doubly expressing glioblastoma cells into brain followed by treatment with WT1 peptide vaccine, anti-PD-1 antibody, or the combination of the two, and survival of each therapy was compared. CD45
RESULTS
RESULTS
Most mice seemed to be cured by the combination therapy with WT1 peptide vaccine and anti-PD-1 antibody, which was much better survival than each monotherapy. A large number of CD4
CONCLUSION
CONCLUSIONS
Our results clearly demonstrated that WT1 peptide vaccine and anti-PD-1 antibody therapies worked in the different steps of cancer-immunity cycle and that the combination of the two therapies could work synergistically against glioblastoma.
Identifiants
pubmed: 34355173
doi: 10.1093/noajnl/vdab091
pii: vdab091
pmc: PMC8331049
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdab091Informations de copyright
© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Curr Opin Immunol. 2008 Apr;20(2):211-20
pubmed: 18502632
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cancer. 2017 Mar 1;123(5):734-750
pubmed: 27875627
Lancet Oncol. 2014 Sep;15(10):1100-8
pubmed: 25163906
J Clin Oncol. 2013 Nov 10;31(32):4085-91
pubmed: 24101040
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Nat Rev Clin Oncol. 2019 Jul;16(7):405-406
pubmed: 30867572
Oncotarget. 2018 Nov 13;9(89):36029-36038
pubmed: 30542516
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Front Immunol. 2018 Mar 22;9:610
pubmed: 29623082
JAMA. 2018 Dec 4;320(21):2195-2196
pubmed: 30419097
Clin Cancer Res. 2009 Sep 1;15(17):5323-37
pubmed: 19723653
Neuro Oncol. 2016 Feb;18(2):195-205
pubmed: 26323609
Cancer Immunol Immunother. 2019 Feb;68(2):331-340
pubmed: 30430205
J Neurooncol. 2012 Apr;107(2):359-64
pubmed: 22045118
J Neurosurg. 2008 May;108(5):963-71
pubmed: 18447714
Jpn J Clin Oncol. 2006 Apr;36(4):231-6
pubmed: 16611662
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
Mol Cell Biol. 2005 Nov;25(21):9543-53
pubmed: 16227604
Br J Haematol. 2018 Jul;182(2):287-290
pubmed: 28542830
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Neurol Med Chir (Tokyo). 2016 Jul 15;56(7):355-60
pubmed: 27087194
Cancer Immunol Immunother. 2021 Jan;70(1):253-263
pubmed: 32696072
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Jpn J Clin Oncol. 2010 May;40(5):377-87
pubmed: 20395243